Adney
American taxpayers may have overpaid for Mylan’s EpiPen shot by as much as $US1.27 billion ($1.71 billion) highly developed than the last decade, according to a US position footnote.
Mylan to trigger generic EpiPen
The drug maker’s generic EpiPin will sell for half the cost of its branded product in the middle of criticism from the public and lawmakers on summit of big price hikes.
Senator Charles Grassley, a Republican politician from Iowa, on the subject of Wednesday posted a copy of a description by the Department of Health and Human Services’ Office of the Inspector General.
The description says that Mylan, by classifying the dynamism-saving allergy shot as a generic drug rather than a brand-make known product, shortchanged the Medicaid program for the needy.
This post was created with our nice and easy submission form. Create your post!
